Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) entered into an agreement to acquire Virex Health, Inc. for $22 million on January 14, 2022. As consideration for the merger, the equityholders of Virex will receive $12 million, subject to certain adjustments (closing consideration), and in addition, subject to achievement of certain regulatory …SAN DIEGO, July 20, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter Sorrento Therapeutics, Inc.'s Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holders. SAN DIEGO, July 20, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving …Headline. Sorrento Therapeutics (NASDAQ:SRNE) Stock Price Passes Below 200 Day Moving Average of $0.11. marketbeat.com - February 9 at 4:17 AM. Sorrento Therapeutics (NASDAQ:SRNE) Coverage Initiated at StockNews.com. americanbankingnews.com - February 9 at 1:30 AM. Sorrento Therapeutics, Inc. (0L85.L) finance.yahoo.com - …The two main types of listening are discriminative and comprehensive. On top of the two basic types of listening, there are more specific types: informational, critical, therapeuti...Find company research, competitor information, contact details & financial data for SORRENTO ENTERPRISES of Chennai, Tamil Nadu. Get the latest business insights …View Sorrento Therapeutics, Inc SRNEQ investment & stock information. Get the latest Sorrento Therapeutics, Inc SRNEQ detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Sorrento Therapeutics (OTC:SRNEQ) misrepresented its business location in its Chapter 11 filing last year, the bankruptcy watchdog for the U.S. Justice Department said, urging the case to be ...SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and ...Jul 5, 2023 · SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ) today announced positive results from a China phase IIa study of Abivertinib on R/R MZL and its plan for a... Stock analysis for Sorrento Therapeutics Inc (SRNE:US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.9 Jan 2023 ... 09, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released unblinded Phase 1b study data of its oral ...SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its ...On February 13, 2023 (the "Petition Date"), Sorrento Therapeutics, Inc., and one (1) affiliated debtor (collectively, the "Debtors") filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code.The Debtors' bankruptcy cases are jointly administered under Case No. 23-90085 before the Honorable Christopher M. Lopez in …Crocheting has gained immense popularity in recent years, and it’s no surprise why. Not only is it a relaxing and therapeutic hobby, but it also allows you to create beautiful and ...About Sorrento Therapeutics, Inc. Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease ...Mar 29, 2023 · SAN DIEGO, March 29, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer ... Sep 22, 2023 · SAN DIEGO, Sept. 22, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving... Aug 2, 2021 · About Sorrento Therapeutics, Inc. Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento's multimodal ... Oncolytic Viruses (Seprehvir™, Seprehvec™) Oncolytic Immunotherapies Sorrento’s oncolytic viral vector assets are a modified version of the common human herpes simplex virus (HSV-1). Seprehvir has been designed with the ability to specifically destroy tumor cells while also stimulating anti-tumor patient immune responses. As part of its global clinical …18 Feb 2023 ... SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form ...SAN DIEGO, Sept. 22, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, announced the consummation on September 21, 2023, of the previously announced sale to Scilex …Jul 20, 2023 · Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease ... Sorrento Therapeutics Inc., a firm working to develop cancer and Covid-19 treatments that filed for bankruptcy after being targeted by short sellers, received court approval to liquidate in bankruptcy. US Bankruptcy Judge Chris Lopez approved the plan during a hearing on Thursday. Sorrento’s funds have dwindled during the court process, …Feb 13, 2023 · Find the latest news headlines from Sorrento Therapeutics, Inc. Common Stock (SRNE) at Nasdaq.com. Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19Young Living Essential Oils is a company that specializes in providing natural, therapeutic-grade essential oils and oil-infused products. Their website is a great resource for tho...Sorrento Therapeutics, Inc. is an Equal Opportunity Employer and offers candidates an attractive salary and comprehensive benefits package that includes ...Oct 18, 2023 · Sorrento said its shareholders are likely out-of-the money. Alternative restructuring lacks funding, creditor lawyer says. Shareholders of bankrupt Sorrento Therapeutics Inc. are unlikely to recover any money under a proposed debt repayment plan, company and creditor lawyers said Wednesday. Sorrento is moving forward with a plan to sell its ... According to the current price, Sorrento Therapeutics is 2,500.00% away from the 52-week low. What was the 52-week high for Sorrento Therapeutics stock? The high in the last 52 weeks of Sorrento ... SORRENTO THERAPEUTICS : HC Wainwright Adjusts Sorrento Therapeutics' Price Target to $26 From $30, Keeps Buy Rating. 21-08-09. MT. Sorrento Therapeutics, Inc. Announces Positive Results of Phase 1b Study of COVI-MSC Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate.Dec 19, 2023 · Share this article. Sorrento Therapeutics has been granted a patent for variant anti-OX40 antibodies that mimic the activity of OX40L, enhancing T cell clonal expansion and differentiation. The antibodies have improved binding affinity and agonistic activity compared to the wild type antibody. They specifically bind to OX40 receptors on ... Walk-in tubs have become increasingly popular among seniors for their safety features and therapeutic benefits. However, one important consideration when purchasing a walk-in tub i...We would like to show you a description here but the site won’t allow us.6 days ago · Sorrento subsidiary Scilex to go public in SPAC merger with Vickers Vantage. Get the latest news and real-time alerts from Sorrento Therapeutics, Inc. (SRNEQ) stock at Seeking Alpha. May 18, 2022 · SRNE. SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and ... Sorrento Therapeutics, Inc.'s Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holders. SAN DIEGO, July 20, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving …Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) entered into an agreement to acquire Virex Health, Inc. for $22 million on January 14, 2022. As consideration for the merger, the equityholders of Virex will receive $12 million, subject to certain adjustments (closing consideration), and in addition, subject to achievement of certain regulatory …Sauna steam rooms have been around for centuries, and their popularity has only increased in recent years. These relaxing and therapeutic spaces offer a range of benefits for both ...PALO ALTO, Calif., Oct. 07, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, retains Warshaw Burstein, LLP and …The two main types of listening are discriminative and comprehensive. On top of the two basic types of listening, there are more specific types: informational, critical, therapeuti...Find the latest Sorrento Therapeutics, Inc. (SRNEQ) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Oct 18, 2023 · Sorrento said its shareholders are likely out-of-the money. Alternative restructuring lacks funding, creditor lawyer says. Shareholders of bankrupt Sorrento Therapeutics Inc. are unlikely to recover any money under a proposed debt repayment plan, company and creditor lawyers said Wednesday. Sorrento is moving forward with a plan to sell its ... Sorrento Therapeutics' stock was trading at $0.1235 at the beginning of the year. Since then, SRNE stock has decreased by 77.3% and is now trading at $0.0280. View the best growth stocks for 2024 here. In therapeutic settings, understanding the dynamics and relationships within a family system is crucial for effective treatment. One tool that has proven to be invaluable in this p...The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 15 cents ...The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 15 cents ...Shares of biopharmaceutical company Sorrento Therapeutics (US:SRNE) rallied as high as 6.5% on Thursday following the release of news that the company entered a term sheet to acquire Ancora Medical.SAN DIEGO, April 25, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer ...About Sorrento Therapeutics, Inc. Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease ...Get the latest Sorrento Therapeutics Inc (SRNEQ) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …SAN DIEGO, May 14, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer ...Sorrento Therapeutics Chairman and CEO Henry Ji joins Yahoo Finance Live to discuss the Covishield antibody Sorrento is developing, the timeline for getting FDA approval, cancer treatment research ...Apr 25, 2023 · Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease ... News Sorrento Therapeutics, Inc. Second Modified Joint Liquidation Plan and DIscllosure Statement Approved for Sorrento Therapeutics, Inc. Best financial portal +951% of historical performance More than 20 years at your side + 950,000 members Quick & easy cancellation Our Experts are here for you OUR EXPERTS ARE HERE FOR …18 Feb 2023 ... SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form ...Dec 1, 2023 · By. Rochdi Rais. -. December 1, 2023. 1930. In a crucial turn of events, Texas bankruptcy judge Chris Lopez has greenlighted Sorrento Therapeutics Inc.’s Chapter 11 liquidation plan. This plan, set to unfold over the next five months, could potentially grant the beleaguered drug developer a chance to explore alternatives to liquidation. Karyopharm Therapeutics Inc. 0.38%. $148.89M. SRNEQ | Complete Sorrento Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.News & Events · Events Calendar · Presentations · SEC Filings · Stock · Governance ... Senior Vice President Neurotherapeutics BU. Dr. Nahama...22 Feb 2023 ... Assuming this decision is finalized, Sorrento will be able to continue normal business operations during its bankruptcy process. However, ...Sorrento Therapeutics Inc. Please post the News, Catalysts, Speculation, Questions, Discussions, No harmful content is allowed. Freedom of speech is welcome here. Research before posting. Do not engage in slander. Be civil and do not spam. ... She sounds willing to push this to be posted on the SRNEQ stock news site but needs more E-Trade …May 14, 2023 · SAN DIEGO, May 14, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer ... About Sorrento Therapeutics, Inc. Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease ...Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of …DAR T (Dimeric Antigen Receptor-T Cell) Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked ...13 Feb 2023 ... Sorrento has filed for Chapter 11 in order to protect its assets. By Eddie Pan, InvestorPlace Financial News Writer Feb 13, 2023, 2:45 pm EST ...Lawyers for biopharmaceutical company Sorrento Therapeutics disputed allegations that they committed bankruptcy fraud, saying that a bank account and …Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.About Sorrento Therapeutics, Inc. Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease ...Sorrento Therapeutics, Inc. is an Equal Opportunity Employer and offers candidates an attractive salary and comprehensive benefits package that includes ...About Sorrento Therapeutics, Inc. Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease ...Stock analysis for Sorrento Therapeutics Inc (SRNEQ:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.About Sorrento Therapeutics, Inc. Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease ...Apr 25, 2023 · PALO ALTO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”) announced that its majority stockholder, Sorrento Therapeutics, Inc. (OTC: SRNEQ ... Sep 22, 2023 · Overview History Leadership Board of Directors Research Pipeline COVID-19 Immunotherapy Pain Lymphatic Drug Delivery Product Candidates Clinical Trials Manufacturing Subsidiaries Partnership Investors News & Events News Releases Events Presentations SEC Filings Stock Quote & Chart Corporate Governance Governance Overview Committee Composition May 18, 2022 · SRNE. SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and ... Sorrento Therapeutics, Inc. is an Equal Opportunity Employer and offers candidates an attractive salary and comprehensive benefits package that includes ...Sorrento Therapeutics, Inc. SAN DIEGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the unexpected passing of Mr. Najjam Asghar, Chief ...The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 15 cents ...Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19Sorrento Therapeutics (OTC:SRNEQ) misrepresented its business location in its Chapter 11 filing last year, the bankruptcy watchdog for the U.S. Justice Department said, urging the case to be ...Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and ...Item 1.03. Bankruptcy or Receivership. Ongoing Litigation As previously disclosed, Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") had been engaged in arbitration before the American Arbitration Association against NantPharma, LLC ("NantPharma") relating to alleged breaches of the May 14, 2015 Stock Sale and …
Jan. 20, 2022, 09:25 AM. Sorrento Therapeutics Inc (NASDAQ:SRNE) has released new data on STI-9167, an advanced stage antibody against COVID-19. The antibody was discovered and developed in an .... Hacking application
17 Feb 2023 ... SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an update to its previously ...We would like to show you a description here but the site won’t allow us.Mar 29, 2023 · SAN DIEGO, March 29, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer ... 14 Feb 2023 ... San Diego's Sorrento Therapeutics filed for Chapter 11 bankruptcy protection this week after a setback in a complex, long-running legal battle ...Sorrento Therapeutics (OTC:SRNEQ) misrepresented its business location in its Chapter 11 filing last year, the bankruptcy watchdog for the U.S. Justice Department said, urging the case to be ...Antibody-drug conjugates (ADCs) are targeted immunotherapies that utilize potent cytotoxic drugs conjugated to antibodies via chemical linkers. This increases the efficacy of chemotherapeutic agents by effectively targeting the drug directly to cancer cells. Thus, ADCs also have reduced side effects because targeting the cancer cells means less ...30 Sorrento Therapeutics (USA) Scilex Pharmaceuticals (USA) 31 Sun Pharmaceutical (India) Ocular Technologies (USA) 294 S. Sharma, K. Singh and V. A. rya .Dec 1, 2023 · By. Rochdi Rais. -. December 1, 2023. 1930. In a crucial turn of events, Texas bankruptcy judge Chris Lopez has greenlighted Sorrento Therapeutics Inc.’s Chapter 11 liquidation plan. This plan, set to unfold over the next five months, could potentially grant the beleaguered drug developer a chance to explore alternatives to liquidation. Walk-in tubs are becoming increasingly popular among seniors who want to maintain their independence and safety while bathing. Walk-in tubs provide a safe and comfortable bathing e...Complete Sorrento Therapeutics Inc. stock information by Barron's. View real-time SRNEQ stock price and news, along with industry-best analysis. Sep 22, 2023 · SAN DIEGO, Sept. 22, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving... Find the latest Sorrento Therapeutics, Inc. (SRNEQ) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Thanksgiving is a time of gratitude, family, and gathering around a bountiful meal. While it’s often seen as a holiday for children, adults can also find joy and relaxation during ...Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case. SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Sorrento …According to the U.S. Food and Drug Administration (FDA), a drug with a narrow therapeutic range (NTI) is one with a narrow range between the drug’s risks and its benefits. The NTI....
Popular Topics
Christmas tree decorators near me | Sorrento Therapeutics, Inc. announced that on March 16, 2023, the LA County Superior Court confirmed an arbitration award of $125 million in damages, to be paid by NantPharma. The award reflects the values of lost milestones for the approval of the drug Cynviloq® for the treatment of breast and lung cancers.Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.Sorrento Therapeutics, Inc. (OTC: SRNEQ) sold all of the shares, preferred shares and warrants that it held in Scilex Holding Company (Nasdaq: SCLX) for $110 …...
Kings warriors | SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of …Lawyers for biopharmaceutical company Sorrento Therapeutics disputed allegations that they committed bankruptcy fraud, saying that a bank account and …Jul 6, 2021 · About Sorrento Therapeutics, Inc. Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento's multimodal ... ...
Water level lake oroville | We would like to show you a description here but the site won’t allow us.2 Feb 2022 ... ... news, portfolio management resources, international market data ... Sorrento Therapeutics CEO details CoviShield neutralizing antibody and cancer ......
Macos update | Stock analysis for Sorrento Therapeutics Inc (SRNEQ:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.SAN DIEGO, Feb. 16, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat ......
Barcelona vs club america | Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19SAN DIEGO, July 20, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the …...
Mia khalifa song | Nov. 07. CI. Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Its Executive Vice President. Nov. 07. CI. Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million. Nov. 02. CI.Apr 4, 2023 · SAN DIEGO, April 4, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer ... Mar 17, 2023 · Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, announced that on March 16, 2023, the LA ... ...